logo

For the Inventor, By the Inventor

Valby, Denmark

Ann-Louise Bergstrôm

This inventor holds 10 USPTO granted patents and 1 published patent application. Top assignee: H. Lundbeck A/s. Active years: 2019-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ann-Louise Bergstrôm. Retrieved from https://idiyas.com/inventor/ann-louise-bergstrôm

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 

% Patents Active = 100.0

Average Co-Inventor Count = 12.1

ph-index = 8

Forward Citations = 91(Granted Patents)


Company Filing History:

goldMedal10 out of 513 
 
H. Lundbeck A/s
 patents

Years Active: 2019-2023

Loading Chart...
10 patents (USPTO):Explore Patents
1. 11542323 - Agents, uses and methods for the treatment of synucleinopathy (2023-01-03),
2. 11421024 - Agents, uses and methods for the treatment of synucleinopathy (2022-08-23),
3. 10800836 - Agents, uses and methods for the treatment of synucleinopathy (2020-10-13),
4. 10647764 - Agents, uses and methods for the treatment of synucleinopathy (2020-05-12),
5. 10647763 - Agents, uses and methods for the treatment of synucleinopathy (2020-05-12),
6. 10640554 - Agents, uses and methods for the treatment of synucleinopathy (2020-05-05),
7. 10364285 - Antibodies for the treatment of synucleinopathy (2019-07-30),
8. 10358484 - Antibodies for the treatment of synucleinopathy (2019-07-23),
9. 10358483 - Antibodies for the treatment of synucleinopathy (2019-07-23),
10. 10358482 - Antibodies for the treatment of synucleinopathy (2019-07-23),

Title: Ann-Louise Bergstrøm: Innovator in Synucleinopathy Treatment

Introduction

Ann-Louise Bergstrøm is a prominent inventor based in Valby, Denmark. She has made significant contributions to the field of medical research, particularly in the treatment of synucleinopathies. With a total of 10 patents to her name, her work focuses on developing novel therapeutic agents for neurodegenerative diseases.

Latest Patents

One of her latest patents involves agents, uses, and methods for the treatment of synucleinopathy. This invention relates to novel monoclonal anti-alpha-synuclein antibodies. These antibodies can be utilized for treating various forms of synucleinopathy, including Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease, combined Alzheimer's and Parkinson disease, pure autonomic failure, and multiple system atrophy.

Career Highlights

Ann-Louise Bergstrøm is currently associated with H. Lundbeck A/S, a leading pharmaceutical company specializing in brain diseases. Her innovative research has positioned her as a key figure in the development of treatments for complex neurological conditions.

Collaborations

Throughout her career, Ann-Louise has collaborated with notable professionals in her field, including Pekka Kallunki and Karina Fog. These partnerships have enhanced her research and contributed to the advancement of therapeutic strategies for synucleinopathies.

Conclusion

Ann-Louise Bergstrøm's work exemplifies the impact of innovation in the medical field, particularly in addressing challenging neurodegenerative diseases. Her contributions continue to pave the way for new treatment options that can improve the quality of life for patients suffering from these conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…